Pay in 4 interest-free payments of $5.46 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Michaelis M, Geiler J, Naczk P, Sithisarn P, Leutz A, Doerr HW, et al
People are filing Ozempic lawsuits alleging they developed unexpected and severe side effects from the drug, which is also called semaglutide
By Product: Ozempic dominates, Tirzepatide products growing fastest Ozempic (semaglutide 0.5mg/1mg/2mg weekly subcutaneous injection) dominated the GLP-1 receptor agonist market with approximately 35.12% market share in 2025, driven by its combination of robust clinical efficacy data, early market entry, broad diabetes label, established prescriber relationships, and expanded off-label use for weight management before Wegovy's commercial scale-up
Mondelli, M
The Journal of Biological Chemistry , 294 (29), 1134211353
US$ 26.24
US$ 28.60
US$ 20.98
